RxDoctor Payments Data

Stella Lee-Maier

Optometrist · Sparta, NJNPI 1841678927

Payments from drug & device makers

$3,048in general payments, 2019–2025

Across 79 payments — averaging $38.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Biotissue Holdings Inc.$168
  • AbbVie$149
  • Sun Pharmaceutical Industries Inc.$146
  • Oyster Point Pharma, Inc.$116
  • Sight Sciences, Inc.$113
  • plus $592 from 11 others

What the payments were for

  • Travel & lodging$99333%
  • Food & beverage$2,05567%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,048 in reported general payments places this provider in the 85th percentile of 1,357 optometrist providers in New Jersey.

See all optometrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$201,361
Medicare patients
519
Services billed
2,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast50$45,826
RestasisCyclosporine32$42,277
LumiganBimatoprost58$35,698
VevyeCyclosporine26$24,483
CombiganBrimonidine Tartrate/Timolol46$22,569
XdemvyLotilaner11$19,901
VyzultaLatanoprostene Bunod29$14,406
TyrvayaVarenicline Tartrate16$10,140
Cyclosporine13$9,634
Fluorometholone100$6,588
RocklatanNetarsudil Mesylat/Latanoprost11$5,111
Latanoprost366$4,384
Brimonidine Tartrate71$4,340
SimbrinzaBrinzolamide/Brimonidine Tart21$4,218
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat224$3,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$149$100,544136 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$102$60,23379 claims
Harrow Eye, LLCVevye$16$24,48326 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$55$19,90111 claims
Oyster Point Pharma, Inc.Tyrvaya$116$10,14016 claims
AlconSimbrinza$102$4,21821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 optometrist providers in New Jersey.

Other optometrist in Sparta

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →